drug

RGX-202

1 story · latest Aug 6, 2026

Status: Investigational
Trials: 1 registered trial in coverage

Relationships

Developed by REGENXBIO Inc.

Timeline

Regenxbio reports Q2 2026 results, cites Duchenne trial win and new AbbVie funds

Aug 6Quarterly updateAbbVie REGENXBIO Inc.

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.